A trial of bevacizumab with chemotherapy for children and teenagers who have soft tissue sarcoma that has spread (BERNIE)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Children's cancers
Soft tissue sarcoma




Phase 2

This trial is looking at bevacizumab alongside chemotherapy for soft tissue sarcoma that has spread to another part of the body (metastatic sarcoma).  Bevacizumab is also known as Avastin.

The trial is for children and teenagers up to the age of 18 who have not had any other treatment for soft tissue sarcoma after it has spread. We use the term ‘you’ in this summary, but if you are a parent, we are referring to your child.

Doctors treat soft tissue sarcoma that has spread with chemotherapy and either radiotherapy or surgery (or both). In this trial, researchers want to see if adding a drug called bevacizumab helps.

Bevacizumab is a type of biological therapy called a monoclonal antibody. The aim of this trial is to see if having bevacizumab alongside chemotherapy is better than chemotherapy alone for children and young people with soft tissue sarcoma that has spread.

Who can enter

You may be able to enter this trial if you

  • Are at least 6 months old but less than 18 years old
  • Have soft tissue sarcoma that has spread from where it started to elsewhere in your body
  • Have satisfactory blood test results
  • Are willing to use a reliable form of contraception if you are sexually active and there is any chance you or your partner could become pregnant

You cannot enter this trial if you

  • Have sarcoma that has spread to your brain or spinal cord, or that is pressing on your spinal cord (spinal cord compression)
  • Have sarcoma that is growing into a large blood vessel
  • Have had any other cancer treatment that reaches your whole body (systemic treatment Open a glossary item)
  • Need to have surgery or radiotherapy straight away – your doctors can advise you about this
  • Have a wound or broken bone that has not healed
  • Have an ulcer in your stomach or gut (peptic ulcer Open a glossary item)
  • Have had an experimental drug or taken part in another clinical trial in the last month
  • Have a high risk of bleeding – the trial doctors can advise you about this
  • Have any other medical condition that the trial team think could affect you taking part in this study
  • Are known to be very sensitive to any of the drugs included in this study or to other monoclonal antibodies
  • Take daily aspirin or a drug called clopidogrel to prevent blood clots
  • Have had any other type of cancer
  • Are pregnant or breastfeeding

Trial design

This is a phase 2 trial. It will recruit about 150 children and teenagers. It is a randomised trial. The people taking part are put into 1 of 2 treatment groups by computer. Neither you nor your doctor can decide which group you are in.

Half the people taking part have bevacizumab alongside chemotherapy. The other half have chemotherapy alone.

The chemotherapy in this trial takes about 18 months all together and is in different phases. The first phase is called induction therapy and lasts about 6 to 7 months. You have drugs called ifosfamide, vincristine, and Actinomycin D. This treatment plan is called IVA. You have IVA in 3 week cycles of treatment. In the first 4 treatment cycles, you also have a drug called doxorubicin. You have all these drugs through a drip into a vein.

If you are in the group having bevacizumab, you have this through a drip into a vein once in each treatment cycle. You have it on the same day as your chemotherapy.

Everybody taking part has 9 cycles of induction chemotherapy all together. After about 6 cycles of treatment, your doctors will talk to you about whether or not you need to have radiotherapy or surgery (or both). If you have surgery, this will be after the 6th cycle of chemotherapy. If you have radiotherapy, this will start at the same time as the 8th cycle of chemotherapy.

The next phase of treatment is called maintenance therapy and lasts for about a year. You have 2 drugs called cyclophosphamide and vinorelbine in 4 week cycles of treatment.

You have vinorelbine through a drip into a vein 3 times in each cycle. You take cyclophosphamide as tablets every day. If you are in the group having bevacizumab, you have it once every 2 weeks during this phase. As before, you have it through a drip into a vein on the same day as you have chemotherapy.

When you finish the maintenance therapy, you move into the follow up phase of the trial which lasts for at least 4 years. You don’t have any more treatment, but the researchers monitor you for any signs of your sarcoma coming back.

The trial team will ask to take extra blood samples before you start treatment and then 6 times during the study. They will use these samples to look for substances called biomarkers, which can help to show doctors how well a treatment is working. You don’t have to give these samples for research if you don’t want to.

Hospital visits

You will see the trial team and have some tests before you start treatment. The tests include

The researchers will also take a sample of your sarcoma (a biopsy Open a glossary item).

During induction therapy, you go to hospital on 3 or 4 days in each 3 week treatment cycle. During the maintenance phase, you go to hospital 3 times in each 4 week cycle.

Throughout your treatment, you have regular blood tests and urine tests. You have a scan every 3 months.

During the follow up phase, you have hospital visits about once every 3 months for 18 months, then once every 6 months for the next 2½ years.

Side effects

The common side effects of chemotherapy include

The side effects of bevacizumab include

  • High blood pressure
  • Allergic reaction
  • Kidney problems
  • Heart problems
  • Delayed wound healing

We have more information about bevacizumab, ifosfamide, vincristine, Actinomycin D, doxorubicin, cyclophosphamide and vinorelbine in our Cancer drugs section.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Julia Chisholm

Supported by

European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 5371

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page